In prostate cancer, different genomic rearrangements can occur, such as the most common fusion of androgen receptor TMPRSS2 with ERG. miR-204 is a TMPRSS2/ERG oncofusion negative regulator and can act as a tumor suppressor or oncomiR, regulating the genes under androgen receptor control [52]. This evidence concerns the gene ERG and prostate cancer.